LSE News & Analysis
London Stock Exchange · 3 articles
Market Mood
AstraZeneca (AZN) Shares Drop 9% After Heart Drug Trial Failure
AstraZeneca's (AZN) stock fell as much as 9% following the failure of its experimental heart drug, Wainua, in a late-stage clinical trial. The trial did not achieve its primary goal of reducing deaths and heart-related emergencies over 140 weeks when compared to a placebo. The stock was last recorded down 8.9% in London, marking the company's worst performance since March 2020. This decline indicates significant market concern over the company’s pipeline and its impact on future earnings.
Read More: AstraZeneca (AZN) Shares Drop 9% After Heart Drug Trial Failure
FTSE 100 Stocks Fall Amid U.S.-Iran Fears and AstraZeneca Trial Setback
The FTSE 100 index fell as concerns over rising tensions between the U.S. and Iran impacted market sentiment. AstraZeneca (AZN) faced pressure after its trial results did not meet expectations, contributing to a decline in its stock price. The uncertainty surrounding geopolitical events can lead to increased volatility in markets, as seen with the FTSE 100's reaction. This matters for ordinary investors as geopolitical tensions can create fluctuations in stock values and investment returns.
Read More: FTSE 100 Stocks Fall Amid U.S.-Iran Fears and AstraZeneca Trial Setback
EDF Extends Sizewell B Nuclear Plant Lifespan by 20 Years
EDF has secured an agreement with the UK government to extend the operational life of Sizewell B until 2055, adding 20 years to its initial end date of 2035. This nuclear power plant, which began operations in 1995, currently provides energy to over two million homes and represents 3% of the UK's energy supply. The deal will involve approximately £800 million in investments and help safeguard 900 jobs, according to EDF's station director. This extension is significant for energy stability and job retention in the region, impacting the UK’s ongoing energy strategy.
Read More: EDF Extends Sizewell B Nuclear Plant Lifespan by 20 Years